Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. 2009

Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
Institute of Hematology and Blood Transfusion, Department of Experimental Virology, U Nemocnice 1, 12820 Prague 2, Czech Republic. danap@uhkt.cz

Tattooing has been shown to be very efficient at inducing immunity by vaccination with DNA vaccines. In this study, we examined the usability of tattooing for delivery of peptide vaccines. We compared tattooing with subcutaneous (s.c.) needle injection using peptides derived from human papillomavirus type 16 (HPV16) proteins. We observed that higher peptide-specific immune responses were elicited after vaccination with the simple peptides (E7(44-62) and E7(49-57)) and keyhole limpet hemocyanin-(KLH)-conjugated peptides (E7(49-57), L2(18-38) and L2(108-120)) with a tattoo device compared to s.c. inoculation. The administration of the synthetic oligonucleotide containing immunostimulatory CpG motifs (ODN1826) enhanced the immune responses developed after s.c. injection of some peptides (E7(44-62), KLH-conjugated L2(18-38) and L2(108-120)) to levels close to or even comparable to those after tattoo delivery of identical peptides with ODN1826. The highest efficacy of tattooing was observed in combination with ODN1826 for the vaccination with the less immunogenic E6(48-57) peptide and KLH-conjugated and non-conjugated E7(49-57) peptides which form the visible aggregates that could negatively influence the development of immune responses after s.c. injection but probably not after tattooing. In summary, we first evidenced that tattoo administration of peptide vaccines that might be useful in some cases efficiently induced both humoral and cell-mediated immune responses.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009856 Oncogene Proteins, Viral Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities. Viral Oncogene Proteins,Viral Transforming Proteins,v-onc Proteins,Transforming Proteins, Viral,v onc Proteins
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D005260 Female Females
D006433 Hemocyanins Metalloproteins that function as oxygen transport proteins in the HEMOLYMPH of MOLLUSKS and ARTHROPODS. They are characterized by two copper atoms, coordinated with HISTIDINE residues, that reversibly bind a single oxygen molecule; they do not contain HEME groups. Hemocyanin,alpha-Haemocyanin,alpha-Hemocyanin,alpha-Hemocyanins,alpha Haemocyanin,alpha Hemocyanin,alpha Hemocyanins
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
July 2002, Journal of immunology (Baltimore, Md. : 1950),
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
November 1990, The Journal of general virology,
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
May 2016, Cancer immunology, immunotherapy : CII,
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
April 2003, The New England journal of medicine,
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
April 2003, The New England journal of medicine,
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
April 2003, The New England journal of medicine,
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
April 2003, The New England journal of medicine,
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
April 2003, The New England journal of medicine,
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
March 2006, Journal of virology,
Dana Pokorná, and Ingrid Poláková, and Martina Kindlová, and Martina Dusková, and Viera Ludvíková, and Pavel Gabriel, and Lud'a Kutinová, and Martin Müller, and Michal Smahel
December 1994, The Journal of infectious diseases,
Copied contents to your clipboard!